Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-G6 for Glycaemic Control in Type 2 Diabetes
NCT03962010Phase 2Unknown
- Sponsor
- Genexine
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial of GX-G6 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Genexine. Primary endpoint: Change in HbA1c at Week 12. Status: unknown.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03962010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962010.